CPC-087 Monitoring Antiemetic Regimens with Aprepitant in Cancer Patients
نویسندگان
چکیده
منابع مشابه
Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy.
PURPOSE Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy were evaluated. METHODS All data were retrospectively collected from the Kyushu University Hospital's electronic medical record system. Patients age 20 years or older with hematologic malignancies who received multiday chemotherapy were included in the study. All p...
متن کاملAntiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.
We report the occurrence of an acute encephalopathy following ifosfamide infusion, that we believe directly triggered by aprepitant (Emend, Merck & Co., Inc.). Aprepitant, the first neurokinin-1 receptor antagonist, is a new antiemetic indicated for highly and moderately emetogenic chemotherapy, in association with 5-HT3 receptor antagonists and corticosteroids. A 57-year-old woman presented wi...
متن کاملCombination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy
Introduction: With repeated courses of chemotherapy, chemotherapy-induced nausea and vomiting (CINV) becomes progressively more difficult to control. The aim of this study was to evaluate whether the antiemetic efficacy of the triple combination aprepitant, palonosetron and dexamethasone could be sustained for up to six cycles of highly emetogenic chemotherapy (HEC) (cisplatin ≥ 50 mg/m(2) ). ...
متن کاملComparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline-based regimens
Chemotherapy-induced nausea and vomiting is a serious adverse side-effect of anthracycline-based chemotherapy regimens, in patients with breast cancer. A combination of three drugs, 5-hydroxytryptamine (5-HT3) receptor antagonist, aprepitant and dexamethasone, is recommended for antiemetic therapy. Palonosetron (PALO), a novel 5-HT3 receptor antagonist has been identified to be effective agains...
متن کاملAntiemetic therapy in patients receiving cancer chemotherapy.
PURPOSE/OBJECTIVES To examine the currently available antiemetic medications and review their uses in the treatment of chemotherapy-induced nausea and vomiting (NV). DATA SOURCES Published articles and book chapters. DATA SYNTHESIS NV is a common yet potentially serious side effect of chemotherapy. Nurses must understand the physiology of NV, its impact on patients, and the proper use of an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.544